The PMPRB has updated its "Patentee's Guide to
Reporting", a guide intended to help patentees complete the
forms required by the PMPRB for the reporting of sales and pricing,
with information that the PMPRB then uses to assess product
The majority of the changes are cosmetic and are designed to
make the text read more smoothly, but do not introduce any
substantive differences. There are two changes of note, however.
First, the definitions of "patentee" and "former
patentee" have been changed to explicitly reference not only
the patent owner, but any other person who is entitled to the
benefit of a patent. This change seems to be in response to the
recent PMPRB decisions regarding generic
The second noteworthy change deals with the Special Access
Program (SAP) and other situations where no marketing approval has
been issued for a product, yet there have been sales. The reference
to the SAP program reflects the Supreme Court's decision in
Celgene Corp v. Canada (Attorney General)2 that
determined that the Board's jurisdiction extends to sales which
do not originate in Canada but products are sold into Canada to
customers who live in Canada.
The Board's updated reporting guidelines can be found
The PMPRB has also proposed two changes to the Compendium of
Policies, Guidelines and Procedures (the Guidelines) by way of a
recently released Notice and Comment. These proposed changes would
affect products whose prices are near the Non-Excessive Average
Price (NEAP). The first change would reduce the number of
investigations which are triggered by the National Average
Transaction Price (N-ATP).
Currently, the Guidelines require Board Staff to commence an
investigation when the N-ATP of a product exceeds the NEAP by 5%.
This provision has the potential to trigger an excessive number of
The proposed changes would remove this trigger. An investigation
would still be triggered if excessive revenues for a product are
greater than $50,000, if a product's introductory price exceeds
the maximum average potential price by 5% or if the PMPRB receives
The second proposed change would affect the way small amounts of
excess revenues are offset. Currently, excess revenues which are
below the threshold for an investigation must either be offset
under a Voluntary Compliance Undertaking (VCU) or a Board hearing.
This is often an inefficient proposition.
The proposed changes would simply require patentees to offset
excessive revenue "in a timely manner", without further
Comments on the changes are due by May 14, 20102. The
Notice and Comment can be found on the PMPRB website at :
The prospect of an internal investigation raises many thorny issues. This presentation will canvass some of the potential triggering events, and discuss how to structure an investigation, retain forensic assistance and manage the inevitable ethical issues that will arise.
From the boardroom to the shop floor, effective organizations recognize the value of having a diverse workplace. This presentation will explore effective strategies to promote diversity, defeat bias and encourage a broader community outlook.
Staying local but going global presents its challenges. Gowling WLG lawyers offer an international roundtable on doing business in the U.K., France, Germany, China and Russia. This three-hour session will videoconference in lawyers from around the world to discuss business and intellectual property hurdles.
Effective September 1, 2016, the Disposition of Surplus Real Property Regulation to the Ontario Education Act was amended with the intention to reduce barriers to the formation of health and community hubs in Ontario.
Health Canada is proposing to change the way that it regulates non-prescription drugs, natural health products and cosmetics in Canada, which will now be referred to collectively as "self-care products."
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).